Form 4: Myriad Genetics CEO Paul Diaz Sells 15,000 Shares
SEC Form 4
Myriad Genetics CEO Paul J. Diaz sold 15,000 shares of common stock at a price of $26.72 per share on September 11, 2024, under a pre-arranged Rule 10b5-1 trading plan.
Summary
- On September 11, 2024, Paul J. Diaz, the President and CEO of Myriad Genetics Inc., sold 15,000 shares of the company's common stock.
- The sale was executed at a price of $26.72 per share.
- The transaction was conducted under a Rule 10b5-1 trading plan.
- Following the transaction, Diaz directly owns 977,378 shares of Myriad Genetics common stock.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it reports a standard insider transaction under a pre-arranged plan. It doesn't inherently indicate positive or negative prospects for the company.
Industry Context
Insider sales are common and can be for various reasons, including diversification or personal financial planning. The use of a 10b5-1 plan suggests the sale was pre-planned and not based on immediate inside information.
Stakeholder Impact
- The sale of shares by the CEO could be perceived negatively by some shareholders, although the existence of a 10b5-1 plan mitigates this concern.
Key Dates
| Date | Description |
|---|---|
| 09/11/2024 | Date of the transaction: Paul J. Diaz sold 15,000 shares of Myriad Genetics stock. |
| 09/12/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.